Get the Stockscreener App
95.94
1.63%
1.46
Boston Scientific Corp stock is traded at $95.94, with a volume of 8.14M.
It is up +1.63% in the last 24 hours and down -3.23% over the past month.
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
See More
Previous Close:
$94.48
Open:
$95
24h Volume:
8.14M
Relative Volume:
0.84
Market Cap:
$142.31B
Revenue:
$19.35B
Net Income/Loss:
$2.78B
P/E Ratio:
51.32
EPS:
1.8696
Net Cash Flow:
$3.82B
1W Performance:
+4.65%
1M Performance:
-3.23%
6M Performance:
-5.28%
1Y Performance:
+9.08%
1-Day Range:
$94.66
$97.05
1-Week Range:
$90.42
$97.05
52-Week Range:
$85.98
$109.50
Boston Scientific Corp Stock (BSX) Company Profile
Name
Boston Scientific Corp
Sector
Industry
Phone
508-683-4000
Address
300 BOSTON SCIENTIFIC WAY, MARLBOROUGH, MA
Compare BSX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BSX
Boston Scientific Corp
|
96.00 | 140.06B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
ABT
Abbott Laboratories
|
125.28 | 220.33B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
354.59 | 134.83B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.43 | 126.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.31 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
Boston Scientific Corp Stock (BSX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-03-25 | Downgrade | Erste Group | Buy → Hold |
| Sep-08-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-16-25 | Initiated | Leerink Partners | Outperform |
| Apr-16-25 | Upgrade | Needham | Hold → Buy |
| Jan-10-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Oct-18-24 | Downgrade | Needham | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Feb-01-24 | Upgrade | Mizuho | Neutral → Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Jun-30-23 | Initiated | CL King | Buy |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| Mar-29-23 | Initiated | UBS | Buy |
| Dec-22-22 | Initiated | Mizuho | Neutral |
| Dec-20-22 | Resumed | Citigroup | Buy |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-06-22 | Initiated | Wolfe Research | Outperform |
| May-27-22 | Upgrade | Needham | Hold → Buy |
| Apr-13-22 | Resumed | Truist | Buy |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| May-26-21 | Downgrade | Needham | Buy → Hold |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Sep-17-20 | Initiated | Truist | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Peer Perform |
| Apr-22-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-01-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Buy |
| Dec-30-19 | Reiterated | Cowen | Outperform |
| Dec-19-19 | Downgrade | Needham | Strong Buy → Buy |
| Sep-05-19 | Resumed | JP Morgan | Overweight |
| Sep-03-19 | Resumed | Barclays | Overweight |
| May-13-19 | Upgrade | Evercore ISI | In-line → Outperform |
| Nov-28-18 | Initiated | UBS | Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Oct-02-18 | Reiterated | Morgan Stanley | Overweight |
| Sep-07-18 | Reiterated | Needham | Strong Buy |
| Sep-04-18 | Upgrade | Jefferies | Hold → Buy |
| Jul-06-18 | Reiterated | Needham | Strong Buy |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Apr-26-18 | Reiterated | Needham | Strong Buy |
View All
Boston Scientific Corp Stock (BSX) Latest News
Truist Financial Lowers Boston Scientific (NYSE:BSX) Price Target to $120.00 - MarketBeat
Boston Scientific's Global Expansion: What's Behind the Growth? - Yahoo Finance
Will Boston Scientific Corporation stock outperform tech sector in 2025Earnings Overview Report & Stepwise Swing Trade Plans - Улправда
Boston Scientific (BSX) Stock After Hours on Dec. 17, 2025: Analysts Stay Bullish as Shares Close Higher — What to Watch Before Thursday’s Open - ts2.tech
Boston Scientific (NYSE:BSX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Boston Scientific (BSX): Revisiting Valuation After Recent Pullback and Ongoing Growth Momentum - simplywall.st
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors - Yahoo Finance
BSX: Canaccord Genuity Lowers Boston Scientific's Price Target | - GuruFocus
BSX: Canaccord Genuity Lowers Boston Scientific's Price Target | BSX Stock News - GuruFocus
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views? - Finviz
Boston Scientific (NYSE:BSX) Shares Rise After Strong Device Demand - Kalkine Media
UBS reiterates Buy rating on Boston Scientific stock with $140 price target - Investing.com
Transcatheter Heart Valve Replacement Market Size to Reach USD 19.98 Billion by 2033, Growing at a CAGR of 15.32% – SNS Insider - GlobeNewswire Inc.
Boston Scientific Corporation $BSX Position Trimmed by Thurston Springer Miller Herd & Titak Inc. - MarketBeat
Boston Scientific (NYSE:BSX) Price Target Raised to $130.00 - MarketBeat
Gradient Investments LLC Has $22.49 Million Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
B. Riley Wealth Advisors Inc. Takes Position in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific moves part of Israeli operation to Ireland - Business Post
Gastrointestinal Diagnostics (GI) Market to Reach $5.8 Billion by 2030 - GlobeNewswire Inc.
Texas Permanent School Fund Corp Reduces Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
Thrivent Financial for Lutherans Buys 19,264 Shares of Boston Scientific Corporation $BSX - MarketBeat
MASTERINVEST Kapitalanlage GmbH Invests $5.23 Million in Boston Scientific Corporation $BSX - MarketBeat
Lazard Asset Management LLC Buys 372,200 Shares of Boston Scientific Corporation $BSX - MarketBeat
HRT Financial LP Boosts Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Stock Position Boosted by Fullerton Fund Management Co Ltd. - MarketBeat
National Bank of Canada FI Has $150.83 Million Holdings in Boston Scientific Corporation $BSX - MarketBeat
Headlands Technologies LLC Acquires 28,473 Shares of Boston Scientific Corporation $BSX - MarketBeat
Treasurer of the State of North Carolina Has $74.06 Million Position in Boston Scientific Corporation $BSX - MarketBeat
Gilder Gagnon Howe & Co. LLC Has $120.86 Million Stock Holdings in Boston Scientific Corporation $BSX - MarketBeat
Engineers Gate Manager LP Sells 29,586 Shares of Boston Scientific Corporation $BSX - MarketBeat
Pulling back 5.1% this week, Boston Scientific's NYSE:BSX) five-year decline in earnings may be coming into investors focus - Yahoo Finance
Adage Capital Partners GP L.L.C. Has $220.77 Million Holdings in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation (BSX) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade
The Beat: Boston Scientific, Daikin Applied invest big on real estate, Saluda Medica raises $150M IPO - The Business Journals
Analysts Are Bullish on Top Healthcare Stocks: Azenta (AZTA), Boston Scientific (BSX) - The Globe and Mail
Quantinno Capital Management LP Has $36.94 Million Stake in Boston Scientific Corporation $BSX - MarketBeat
Boston Scientific Corporation $BSX Shares Sold by DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main - MarketBeat
Boston Scientific Corporation $BSX Shares Bought by Armistice Capital LLC - MarketBeat
Boston Scientific (BSX) Stock Falls Amid Market Uptick: What Investors Need to Know - Yahoo Finance
Boston Scientific Corp. stock underperforms Thursday when compared to competitors - MarketWatch
TD Cowen reaffirms Boston Scientific stock rating with $115 price target - Investing.com
Boston Scientific Sustains Momentum in the PFA Market: What's Next? - Yahoo Finance
New insurance policy benefits Boston Scientific Intracept procedure - MassDevice
Boston Scientific Stock Is Dropping: Reasons Behind BSX Sell-Off - EBC Financial Group
Boston Scientific (BSX) Extends Losing Streak: What Tuesday’s Close Means Before the Bell on December 10, 2025 - ts2.tech
Boston Scientific Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
A Look Into Boston Scientific Inc's Price Over Earnings - Benzinga
Boston Scientific buys new Minnesota facility for nearly $189M - MassDevice
Boston Scientific Corporation $BSX Shares Purchased by State Street Corp - MarketBeat
Boston Scientific buys major Minneapolis-area property for $188M - NBC Boston
Boston Scientific Corp Stock (BSX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
1.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):